Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin

G. Onose* **, D.F. Mureşanu***, A.V. Ciurea*** ****, C. Daia Chendreanu* *, A. S. Mihaescu*, D.C. Mardare*, I. Andone*, A. Spânu*, A. Popescu*, A. Dumitrescu*, M. Popescu***** V. Grigorean** ***, B. Ungur*, F. Marinescu*, I. Colibâşeanu*, L. Onose******, M. Haras**, A. Sandu*, T. Spîrcu**

*Bagdasar-Arseni* Teaching Emergency Hospital, Bucharest, Romania

**Carolina Davila** (State) University of Medicine and Pharmacy, Bucharest, Romania

***The Neurological Clinic of Iuliu Hatieganu (State) University of Medicine and Pharmacy, Cluj-Napoca, Romania

****The I^th Clinic Division of Neurosurgery, Bagdasar-Arseni Teaching Hospital, Bucharest, Romania

*****The Neurosurgery Division of the County Hospital, Pitesti, Romania

******The Medical Service of Metrorex, Bucharest, Romania

Correspondence to: G. Onose, M.D PhD

*Bagdasar-Arseni* Teaching Emergency Hospital

10-12 Berceni Street, District 4, Bucharest, Romania

Received: September 1st, 2009 – Accepted: September 25th, 2009

Abstract

Background: Discovery of neurotrophic factors - emblematic: the nerve growth factor (NGF) - resulted in better approaching central nervous system (CNS) lesions. Recently, another crucial property has been unveiled: their rather unique pleiotropic effect. Cerebrolysin is a peptide mixture that penetrates the blood-brain barrier in significant amounts and mimics the effects of NGF.

Methods: Comparative analysis: Cerebrolysin treated (10 ml x 2/ day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy). Two lots of patients, admitted in our Physical & Rehabilitation (neural-muscular) Medical - PR(n-m)M - Clinic Division, during 2007-2009: 69 treated with Cerebrolysin (22 F, 47 M; Average: 59.333; Mean of age: 61.0 Years old; Standard deviation 16.583) and 70 controls (41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270) were studied. The total number of assessed items was 13: most contributive in relation with the score of Functional Independence Measure at discharge (d FIM), were: admission (a FIM), number of physical therapy days (PT), number of hospitalization days (H), age (A) and - relatively - days until the first knee functional extension (KE). Concomitantly, the main/ key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters, have been assessed regarding the speed in achieving their functional recovery.

Results: Concerning d FIM, there have not been objectified significant differences between the two lots (p=0.2453) but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters; KE (p=0.0007) and days until the first time recovery of the ability to walk between parallel bars (WPB - p=0.0000) – highly significant differences in favor of Cerebrolysin lot resulted.

Conclusion: Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a comprehensive national, 5 year retrospective, multi-centre - based on unitary data acquisition frame and mathematical apparatus – study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).

Introduction

In 1986, Rita Levi-Moncalcini (from The Cellular Biology Institute, Rome, Italy) and Stanley Cohen (from the Vanderbilt University School of Medicine, Nashville, USA) received the Nobel Prize for discovering neurotrophic factors: the nerve growth factor - NGF - respectively, the epidermal growth factor - EGF. Since then, many other neurotrophic factors have been identified: they are polypeptides, naturally synthesized by all types of cells within the CNS and also by other tissues. Their activity is essential for the NS development (they stimulate cell proliferation and...
Injury/toxic factors and for their neural cells' natural survival in the absence of differentiation, respectively axonal and dendritic growth), for the neural cells' natural survival in the absence of injury/resistance to noxious factors and for their phenotype retaining, during lifetime.

Neurotrophic factors stimulate neural plasticity and synaptic activity, and therefore are important for both: learning processes and for the NS's impressive ability to spontaneously reorganize and thus, clinical adapt(limited) self-recover, after different injuries.

The discovery of neurotrophic factors - emblematic: NGF - resulted in better approaching CNS lesions. Recently, another crucial property has been unveiled: their rather unique pleiotropic effect [1] – i.e. a combined, complex neuroprotection and neurotrophicity (including neural plasticity) stimulation.

CNS injuries are divided into two main categories: primary - which occur (mainly) at the moment of a trauma - and secondary ones, that develop after the initial injury, as a consequence of a complex and rather specific to CNS, patho-physiological events' cascade; they produce effects that may continue for a long time. The secondary injury process (synthetically including: excessive synthesis of nitric oxide and oxidative stress, microglia activation, local inflammation, disturbance of microcirculation, blood-brain barrier dysfunction and the most recently acknowledged "delayed mechanisms of cell death"[2,3,4,5]) leads in vicious circles, to disastrous consequences:

- neuronal necrosis;
- neuronal apoptosis;
- scar and/or cyst/ hygroma formation - with further - pathogenic effects on CNS tissue;
- demyelination;
- disruption of morpho-functional nerve pathways (disconnection) and/or functional uncoupling, such as diaschisis.

Thus, minimizing the secondary damage "cascade" could result in maximizing post-injury favorable evolution/recuperation, including more rapid and consistent neuro-rehabilitative outcomes.

Therefore, the CNS intimate mechanisms of the secondary injuries are, at present, main targets for modern, including pleiotropic, complex therapies.

CNS main pathways for the secondary damage (occurring in the affected area and in its neighborhood):

1. Breakdown of the primary traumatized area's cells.
2. Breakdown of the myelin sheath's structure.
3. Release, from inside the disrupted CNS cells - mitochondria are important sources - of reactive oxygen species (ROS).
4. Microglia activation including pro-inflammatory, with subsequent delivery of cytokines from these injured structures and of wall components, as well (together - in vicious circle) with supplementary amounts of ROS - as a result of ROS peroxidation lesions of membranes' phospholipids (under excessive, post tissue injury - including neural - metabolic, mitochondrial/ cell hyperactivity).
5. Oxidative stress - the (hyper) local metabolic generation of ROS and physiological antioxidants' depletion, with subsequent alteration of some gene expression functions (especially for factors/ transcriptional mechanisms type: NF-kB, PPAR, AP-1) and thus, implying, including synthesis sequences, that stimulates production of pro-inflammatory cytokines - especially interleukins IL-1, IL-6 and tumor necrosis factor (TNF) α – respectively, with concomitantly reduction of related molecules synthesis (but with anti-mediator role - for example: IL-2).
6. Immune imbalance/inflammation.
7. Disorder of local microcirculation and integrity of the blood-brain barrier (with consecutive regional ischemia and edema).
8. Electrolyte disorders, including massive edema - CNS tissue swelling - induced by suddenly installed osmosis (often one of the direct effects of primary injury, too) subsequent to the affected cells which die passively – thus, violent osmosis is also, in such circumstances, a main necrosis mechanism: in necrosis it is the cellular edema which leads to osmosis, with the cell passively dying off.
9. Increase of the nervous tissue metabolism, including oxygen consumption, thus resulting, in the vicious circle, of its sensitivity to hypoxia and - once more – ischemia.
10. Large amounts of tiny molecules - Transient Receptor Potential Member (TRPM) 7 - invade the normal surrounding neurons' membrane surfaces and very probably, mainly through adenil-cyclase, dramatically enhance their oxidative metabolic activity, resulting in more ROS that propagates the damages to an extensive cell (both) apoptosis and necrosis process, in the unaffected neighborhood, too.
11. Resulting in a relative excess of exciting neurotransmitters and massive influx of intracellular (toxic/metabolic destructive) calcium ions (see further).
12. Sequential activation of key-role genes, including (most dangerous for a non-regenerating tissue, like CNS – as neurons lack centrosomes) those for apoptosis - triggering the "mechanisms of delayed cell death": programmed cell suicide and apoptosis-like processes - most recently emphasized, having a longer display and being produced at an intimate level, mainly through metabolic disturbance of aggregated proteins involved in the deep mechanisms of cellular reproductive cycles/vitality-survival [1,6,7].

Briefly, it is worth to synthetically emphasize some of the main beneficial actions but it also limits/side effects - related to the pleiotropic effect subject matter - of one of the most studied and controversially used - including in CNS acute lesions - drug, with strong anti-inflammatory properties: metilprednisolone (MP). The most important action of MP in the acute stage of injury is to inhibit the
lipid peroxidation induced by ROS, thus limiting the secondary damage. The antioxidant effects of MP are not mediated via glucocorticoid receptors: other steroidal anti-inflammatory drugs (SAIDs) do not possess similar antioxidant activity [8].

MP interferes with other neural pathological pathways, too:
- decreases the arachidonic acid release;
- lowers the cellular inflow of calcium ions and subsequently, the apoptosis processes;
- decreases anaerobic metabolism and prevents (toxic) lactate/acidosis accumulation;
- minimizes neurofilaments degeneration;
- reduces post-traumatic nevrax edema and its compressive consequences;
- helps maintaining the neuronal membrane potential and the synaptic transmission.

Adverse actions: in the recent years, the use of high-dose MP has become controversial, mostly based on the risk of serious side effects versus a modest neurological benefit. The steroid side effects are prominent when the treatment is extended beyond 24 hours: pneumonias, septic shocks, wound infection, delayed wound healing, pressure sores, hyperglycemia, deep-vein thrombosis, gastro-intestinal bleedings [9-12].

Other limitations to high-dose MP therapy: the neuroprotective properties of MP have a sharp U-shaped dose-response curve, that requires careful dose calculation; initiation of treatment beyond the 8-hour opportunity window can exacerbate damages: inhibition of axonal budding and synaptogenesis. Considering the long term neurological outcome, the potential of the steroid to attenuate post-injury neural plasticity is probably the most serious concern regarding the administration of high doses of MP.

13. Higher concentrations of calcium ions, extruded on the exterior of the nerve cells’ break, flood the interior of these (and also other, non-affected) neurons [13]. In the attempt of regaining the pressure’s balance of the ionic concentrations, calcium sets off a series of self-destructive cellular events, among which very important is: its interference, at mitochondrial level, with the electron transport/acceptor chain, thus resulting in a greater amount of ROS (Fig. 1).

14. Injury releases amounts of different neurotransmitters higher than usual: catecholamines, endorphins, serotonin and (most “dangerous”, especially in the early post-injury stages) glutamate, the main excitatory normal neurotransmitter; in large, abnormal, amounts without enough valid neurons to respond to, glutamate expresses its toxicity by overloading intact remaining neuronal circuits.

![Fig 1 Glutamate increases Ca\(^{2+}\) cellular influx, activating neuronal nitric oxide-synthetase (nNOS); this enzyme, in the presence of Ca\(^{2+}\) absorbed at mitochondria level, converts nitric oxide (NO) in peroxinitrite (ONOO\(^-\)); one of the most toxic ORS; Ca\(^{2+}\) and ONOO\(^-\), apparently paradoxical, blocks the mitochondrial breathing (in terms of oxidative metabolic hyperactivity, which is induced by Ca\(^{2+}\)); concomitantly/ consequently, at the respiratory chain level, increases the production of ROS. It results: energetical mitochondrial collapse, damaging (predominantly by peroxidation) the membranar lipids - with propensive permeabilisation getting out from mitochondrias and translocating to the nucleus of AIF - and DNA by ROS (mainly ONOO\(^-\)) and respectively, secondary hiperactivation of poly-ADP-ribozo-polymerase (PARP) -1 enzyme; the latter convey the signals of cell suicide by engramated, preformated way on nuclear level, through chemical-energetical revolving plate’s depletion, represented by nicotine-amide-dinucleotide (NAD)+/ATP, resulting a proapoptotic effect, synergically in such cases, with the one of Endonuclease G (Endo G) - after Hong cited by Blackman S A, 2005 [1,3]]
15. Calcium, ROS and endogenous tissue enzymes (proteases, phospholipases, lipoxygenases, cyclooxygenases) work in concert to destroy dead or dying cells.

16. Prostaglandins produce chemotaxis and (supplementary) local/regional vasoconstriction/ischemia.

17. The oxygen breakdown of essential cell lipids (lipid peroxidation) and the other previously exposed pathways, lead, into a vicious circle, to more swelling, by water entering CNS - especially the brain - tissue, from the blood and cerebro-spinal fluids, thus leading, to more cell breakdown and more secondary release of toxic substances, that again, affect blood flow.

18. By-products of many of these reactions, of the events’ cascade pathways, also stimulate the glial cells (first of all the astrocytes, which have a complex, vital role - “housekeeping” - within the NS): to emit “signaling” molecules, instructing to proliferate, in the attempt to replace/repair the destroyed/lost nevraxial tissue; this results mainly, in gliosis and (unfortunately) in scars (a major source for further limits in CNS recovery).

Additionally to the lack of self repair significant skills and to the extensive secondary damages pathways, in the CNS, for reasons yet unclear, there are also strong inhibitors mainly of axonal re-growth. Hence, among the main nevraxial - afore emphasized - limits in self recovery after injuries, there are also some inner obstacles that prevent CNS cells’ regeneration, generically called the "braking" machinery in neurons: tightly related to the Neurite Outgrowth Inhibiting (NOGO) protein and receptors (Schwab et al., since the middle eighties [14,15,16]) and more generally, to the rho family of receptors[17]; this family of receptors relays on a protein called TAJ or TROY and another one - p75 - that acts as an important part of the same family of receptor complex proteins - called TNF receptors - on neurons, responding to growth-inhibitory molecules in myelin and thus, preventing the cable-like axons’ (re)-growth of injured neurons in CNS: acceptance of these inhibitory molecules, like a key fitting a lock and switched-on, results in inhibitory signaling, within the neuron [18].

Today, more than 500 substances are or have been studied for neuroprotective properties.

As traumatic and ischemic injuries in both, the brain and the spinal cord, entail/contain very resembling/rather overlapping - as mechanisms types within the pathophysiological events’ cascade, leading to secondary lesions - the “good news” is: neurotrophic and especially, pleiotropic substances, conceptually (and practically - growing evidences[19]) thus justify a quite large clinical utility spectrum.

Cerebrolysin is a peptide mixture obtained by standardized enzymatic (proteo)lysis breakdown of purified porcine brain proteins. It consists of approximately 25% biologically active low molecular weight peptides and amino acids that are able to penetrate the blood - brain barrier in significant amounts and mimic the effects of NGF. 1 ml of injectable solution contains 215,2 mg of protein lysate and excipients (sodium hydroxide, water). The injectable solution does not contain proteins, lipids, or other antigenic molecules.

As it will be seen further, it targets and counteracts many essential pathways of the secondary damage cascade and concomitantly, stimulates/ facilitates mechanisms of re-adapting and (limited) self repair in CNS injuries, i.e. the corollary - relatively rare and most beneficial - pleiotropic effect:
Cerebrolysin inhibits both µ- and m-calpain in an (also) dose-dependent manner. The protease inhibition is non-competitive and reversible; therefore, Cerebrolysin protects the cytoskeleton elements susceptible to calpain degradation: in neuronal cell cultures, it reduces the loss of (morpho-functional very important) Microtubule-associated protein (MAP) 2, after a cell injury.

Below - some effective, intimate histopathological outcomes of the treatment with Cerebrolysin.

**Indications:** As already emphasized, Cerebrolysin exhibits complex neuroprotective and neurotrophic - pleiotropic - actions. These effects have been investigated and confirmed in various cell culture and animal models of neuro-degeneration and ischemic injuries, as well as in clinical trials.

The window of opportunity in acute stroke is considered to be of 24 hours. Clinical trials have demonstrated significant motor and cognitive improvements in stroke and dementia patients, leading to consistent amendments to their quality of life (QOL).

**Interactions:** Cerebrolysin should not be mixed in perfusion with neutral amino acid solutions. The doses of anti-depressive medication and particularly, of monoamine oxidase inhibitors (MAOIs) should be lowered if used in conjunction with Cerebrolysin. The side effects of Cerebrolysin are infrequent and usually mild and transient: agitation (aggressiveness, insomnia, rarely hallucinations), confusion, tremor, allergic reactions - very rare, in our expertise (fever, skin reactions, pruritus, local vascular reactions, headache, neck pain, limb pain, lower backache, dyspnea, chills, shock-like state), vertigo, headache, hypertension or hypotension, hyperventilation, hypotension or hypotonia, fatigue, depression, apathy, flu-like symptoms, gastrointestinal troubles (loss of appetite, dyspepsia, diarrhea, constipation, nausea, vomiting), rapid injection may cause heat sensation, sweatiness, dizziness, rarely palpitations or cardiac arrhythmias, injection site reactions (irritation, pruritus, burning sensation).

**Contraindications** are: hypersensitivity to the protein lysate or to the excipients; epilepsy, especially grand mal convulsions (Cerebrolysin treatment may increase the frequency of seizures); severe or acute kidney failure; there is no available information on the safety of Cerebrolysin during pregnancy and lactation in humans, though animal studies found no toxic effects; some studies have shown that Cerebrolysin can be safely used in patients with acute hemorrhagic stroke.
Objective

The objective of this study was to assess the outcomes obtained in our PR(n-m)M Clinic Division with Cerebrolysin, compared to patients who did not receive such neuroprotective / neurotophic (pleiotropic) therapy.

Material and methods

The study included two lots of patients, admitted during 2007-2009: 69 treated with Cerebrolysin (22 F, 47 M; Average: 59.333; Mean of age: 61.0 Years old; Standard deviation 16.583) and respectively, 70 - controls (41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270).

Study design

A comparative analysis between Cerebrolysin (10 ml x 2/ day, i.v. x 3 weeks), vs. patients non-treated with Cerebrolysin (all the inpatients received aside, a rather equivalent complex, pharmacological and physical therapy).

The Cerebrolysin treated lot has been constituted on a random base, “naturally” represented by the periods, within the duration of our study, when our hospital’s pharmacy could supply this drug.

Mathematical methodology

Our statistical analysis used, as desired, a differentiation method to assess the validity of outcomes, the T TEST; previously this entailed the mathematical evaluation of the two studied populations’ normality of distribution. Hence, if a population is normally distributed - according to the frequency histogram and the following calculation tools: Min, Max, Aver., St. Dev. - it is to be expected strong validity results of the applied T TEST; if the population is not normally distributed - as it was, mostly the case of the assessed parameters within our study - we applied the CHI SQUARE TEST, by the frequency histogram - giving thus, potential for evaluation to more of our assessed parameters.

There have been done also correlation analysis, to objectify the statistical assessed variables/ phenomena’ dependence, between them, quantified by the calculated
value - through the EPI INFO soft - of the correlation coefficients (positive or negative). Hence, once emphasized a certain dependence between variables, they had to be quantified by regression assays; as it is well known, there are simple regressions (with the generic formula: \( Y = a + bX \), where: \( Y \) = the dependent variable; \( X \) = the independent variable; \( a \) and \( b \) = regression coefficients; \( b \) is also the straight line’s slope, representing the amount in which \( Y \)’s value changes when \( X \)’s value varies by one unit) and multiple ones: applied to this study, all the independent variables (a FIM, PT/KT, H, A, KE, WPB, SR, EXR, CWR, IWR, G, E) are simultaneously intervening. Thus, we were interested in the construction of a mathematical model/ equation, in which the dependent variable \( Y \) is d FIM and the independent variables are: \( X_1 \) (a FIM), \( X_2 \) (PT/KT), etc. The resulting formula was: \( Y = B_0 + B_1 X_1 + B_2 X_2 + \ldots + B_n X_n \) - multiple regression - where: \( Y \) = the dependent variable (d FIM), \( B_0 \) = the tabular appropriate correlation/ regression coefficient, \( B_1 \) = the correlation/ regression coefficient of a FIM, etc.

Fig. 8 The curves for simple and respectively, for multiple regression

Results and discussions

First, two studied populations’ normality distribution level has been assessed, with respect to each main parameter, starting with the first - focused (but) non functional/ analytical - one, PT/KT:

| freq. PT/KT cereb. | freq. PT/KT witness | normal PT/KT cereb. | normal PT/KT witness |
|------------------|--------------------|---------------------|----------------------|
| 0.058            | 0.18518            | 0.20692             | 4                    |
| 0.463            | 0.28397            | 0.25522             | 1                    |
| 0.275            | 0.25577            | 0.20905             | 1                    |
| 0.043            | 0.11372            | 0.0154              | 1                    |
| 0.115            | 0.04204            | 0.04108             | 1                    |
| 0.014            | 0.00767            | 0.00985             | 1                    |
| 0.014            | 0.00082            | 0.00157             | 1                    |
| 0.0014           | 0.00016            | 0.0001              | 1                    |
| 0.0000           | 5.18E-05           | 6                   | 1                    |
| 0.0000           | 1.92E-06           | 1.17E-05            | 1                    |
| 0.0000           | 4.16E-08           | 4.54E-07            | 1                    |
| 0.0000           | 5.31E-10           | 6.92E-08            | 1                    |
| 0.0000           | 9.10E-08           | 0.83762             | 1                    |
| 0.0000           | 5.18E-05           | 6                   | 1                    |

As (also) emphasized by the histogram below, a statistically significant populations’ normality distribution hasn’t been observed:

Fig. 9 Frequency distribution

Fig. 10 Histogram emphasizing the level of the two studied populations’ normality distribution, regarding PT/KT

Accordingly, we proceeded to CHI² TEST assay; the resulted \( p=0.152824 \), emphasizes that statistical
significant differences between the two lots, regarding this parameter have not been objectified:

Table 2  The tabular form of the CHI² TEST results regarding PT/KT

| PT/KT  | Cerebolysin | Witness |
|-------|-------------|---------|
| <10   | 9           | 15      |
| 10-17 | 29          | 30      |
| 18-26 | 17          | 16      |
| >26   | 14          | 9       |

chi² test val. p 0.152824
0.5 val. p 0.076412

Similarly, related to the frequency distribution, we comparatively analyzed the two populations’ normality, regarding the - focused (but) non functional/ analytical - H parameter:

| Average H Cerebolysin | 26.17391304 |
|-----------------------|-------------|
| St. dev. H Cerebolysin| 15.27970253 |
|Average H Witness     | 22.98571429 |
|St. dev. H Witness     | 17.41354866 |

p value 0.126540558

Table 3  Normality distribution values of the two assessed populations, regarding H parameter

| freq. H cer. | freq. H with. | normal cer. | normal with. |
|--------------|---------------|-------------|--------------|
| 6,5          | 0.0145        | 0.1286      | 1            | 0.136765    | 0.175623   |
| 18,5         | 0.3333        | 0.2714      | 23           | 0.276188    | 0.265947   |
| 30,5         | 0.3768        | 0.3714      | 26           | 0.301002    | 0.250478   |
| 42,5         | 0.1159        | 0.1286      | 8            | 0.177039    | 0.146725   |
| 54,5         | 0.1159        | 0.0571      | 8             | 0.056196    | 0.053456   |
| 66,5         | 0.0145        | 0.0286      | 1             | 0.009627    | 0.012113   |
| 78,5         | 0.0145        | 0.0000      | 1             | 0.00089     | 0.001707   |
| 90,5         | 0.0145        | 0.0000      | 1             | 4.44E-05    | 0.00015    |
| 102,5        | 0.0000        | 0.0000      | 0             | 1.2E-06     | 8.16E-06   |
| 114,5        | 0.0000        | 0.0000      | 0             | 1.74E-08    | 2.77E-07   |
| 126,5        | 0.0000        | 0.0143      | 0             | 1.36E-10    | 5.83E-09   |
| 1,000        | 1.0000        | 69           | 70            | 0.957752    | 0.906207   |

As (also) emphasized by the histogram below, a statistically significant normality distribution hasn’t been observed:

Fig. 11 Histogram emphasizing the level of the two studied populations’ normality distribution, regarding H

Therefore, we proceeded to CHI² TEST assay. It resulted p=0.013259, i.e. there has been objectified statistical significant difference, but at limit, between the two lots, regarding H, in “favor” of the Cerebolysin lot.

Table 4  The tabular form of the CHI² TEST results regarding H

| H       | Cerebolysin | Witness |
|---------|-------------|---------|
| <11     | 4           | 15      |
| 11-30   | 46          | 39      |
| 31-50   | 14          | 13      |
| >50     | 5           | 3       |

chi² test val. p 0.013259
0.5 val. p 0.006629

The interpretation of this discriminative result should be done within a wider, more complex context, i.e. the mean duration of H is, from economical objective reasons, limited, thus having - obviously - including administrative constrains in our clinic activity. Hence, one of the main normal medical criterion to discharge a patient is when he/she reaches a plateau in the actual stage of the rehabilitative process (usually of long term). Therefore, a larger number of H, means the respective patient had a prolonged/ sustained, favorable evolution.

The two studied populations’ normality distribution has also been assessed, regarding the d FIM composed/ exhaustive parameter:

Table 5  Normality distribution values of the two assessed populations, regarding d FIM parameter

| freq. d FIM cer. | freq. d FIM with. | normal cer. | normal with. |
|------------------|-------------------|-------------|--------------|
| 6,5              | 0.0580            | 0.0000      | 4            | 0.013924    | 0.001594   |
| 18,5             | 0.0000            | 0.0000      | 0            | 0.03237     | 0.009536   |
| 30,5             | 0.0145            | 0.0143      | 1            | 0.063202    | 0.038648   |
| 42,5             | 0.0725            | 0.0857      | 5            | 0.103636    | 0.106099   |
| 54,5             | 0.0435            | 0.1286      | 3            | 0.142719    | 0.197308   |
| 66,5             | 0.2609            | 0.2571      | 18           | 0.165064    | 0.248557   |
| 78,5             | 0.1884            | 0.3000      | 1321         | 0.160332    | 0.212108   |
| 90,5             | 0.1159            | 0.1143      | 8            | 0.130792    | 0.122613   |
| 102,5            | 0.1304            | 0.0571      | 9            | 0.089606    | 0.048014   |
| 114,5            | 0.0290            | 0.0000      | 2            | 0.051558    | 0.012736   |
| 126,5            | 0.0725            | 0.0429      | 5            | 0.024914    | 0.002289   |
| 1,000            | 1.0000            | 6870        | 0.978117     | 0.999502    |

As emphasized by the histogram below, a statistically significant normality of distribution has been observed:
Accordingly, we could use the T TEST; the results below, statistically significant emphasized the lack of difference between (regarding both, the independent and the dependent, related variables) the global/ synthetic outcomes, in the two lots – a FIM (p=0.3682) and d FIM (p=0.2453):

Table 6 The tabular form of the T TEST results, regarding a FIM and d FIM

| T TEST | a FIM | d FIM |
|--------|-------|-------|
| Average | 53.36231884 | 70.5 |
| St. dev. | 24.37149433 | 28.72281 |
| Average | 54.52857143 | 67.61429 |
| St. dev. | 15.31005299 | 19.22807 |
| p value | 0.36826413 | 0.245307 |

Regarding the comparative assessment of the key focused on neuro-motor rehabilitative outcomes, functional/ analytical parameter, KE, related to the frequency distribution, there hasn't been observed a statistically significant populations’ normality distribution:

Table 7 Normality distribution values of the two assessed populations, regarding KE parameter

| KE | Cerebrolysin | Witness |
|----|--------------|---------|
| <3 | 21           | 28      |
| 3-12 | 18           | 9       |
| 13-22 | 25           | 20      |
| >23 | 5            | 13      |

chi² test val. p | 0.000733 |
0.5 val p | 0.000366 |

The same lack of statistically significant populations’ normality distribution and consequently, similar mathematical methodology and results, were used/ obtained for another key focused on neuro-motor rehabilitative outcomes, functional/ analytical parameter - WPB (p=0.000000):

Table 8 The tabular form of the CHI² TEST results, regarding KE

| WPB | KE |
|-----|----|
| Average | 6.942029 |
| St. dev. | 9.73152 |
| Average | 8.871429 |
| St. dev. | 11.61823 |
| p value | 0.145084 |

Table 9 Normality distribution values of the two assessed populations, regarding WPB parameter

| freq. WPB cereb. | freq. WPB with. | normal cerebrol. | normal with. |
|------------------|----------------|------------------|--------------|
| 2.5 | 0.5652 | 0.5857 | 39 | 41 | 0.087621 | 0.080677 |
| 5.5 | 0.0290 | 0.0000 | 2 | 0 | 0.108054 | 0.098386 |
| 8.5 | 0.0580 | 0.0000 | 4 | 0 | 0.12103 | 0.110515 |
| 11.5 | 0.0580 | 0.0429 | 4 | 3 | 0.123129 | 0.114343 |
| 14.5 | 0.0580 | 0.0286 | 4 | 2 | 0.113775 | 0.109869 |
| 17.5 | 0.0870 | 0.0571 | 6 | 4 | 0.095488 | 0.096562 |
| 20.5 | 0.0725 | 0.0857 | 5 | 6 | 0.07279 | 0.077337 |
| 23.5 | 0.0000 | 0.0286 | 0 | 2 | 0.050397 | 0.057959 |
| 26.5 | 0.0000 | 0.1000 | 0 | 7 | 0.031693 | 0.039508 |
| 29.5 | 0.0000 | 0.0143 | 0 | 1 | 0.018102 | 0.024962 |
| 52.5 | 0.0725 | 0.0571 | 5 | 4 | 1.01E-05 | 4.81E-05 |
| 1,000 | 1,000 | 69 | 70 | 0.822089 | 0.807992 |

Table 10 The tabular form of the CHI² TEST results, regarding WPB

| WPB | Cerebrolysin | Witness |
|-----|--------------|---------|
| <3 | 39           | 41      |
| 3-12 | 11           | 3       |
| 13-22 | 14           | 13      |
| >23 | 5            | 13      |

val. of p | 7.75E-06 |
0.5 val of p | 3.87E-06 |
For the other focused on neuro-motor rehabilitative outcomes, functional/analytical parameters, the number of patients suitable to be introduced in histograms, was not enough for concluding results; therefore, we consider the total number of the studied patients within both lots, to be rather small.

Regarding correlation tests in our study, multiple regression analysis mainly evaluated predictor contributivity matters: Hence, the way – of contributivity/reliability measure - the two analyzed populations aggregate, for (all parameters considered) each studied individual, to the - resulting/ proposed by the EPI INFO soft - optimal appropriate multiple regression formula, regarding the whole predictability level of our study is emphasized in the graphic below:

Additionally, close to the statistical significance limit, the - focused (but) non functional/analytical - parameters: PT/KT (r=5.8520, p=0.0115) and H (r= -4.0070, p=0.0159) were placed, by their predictor contributivity:

| a FIM | PT/KT | H |
|---|---|---|
| 0.8660 | 5.8520 | -4.0070 |
| p | 0.000000 | 0.011572 | 0.015943 |

For the other parameters (again) the number of patients in which these could be assessed, was not large enough for statistical contributivity, according to the multiple regression design/requirements, within these dimensions of the studied lots.

On the other hand, the statistical significance of the discriminative tests’ results that support the hastening, in reaching neurorehabilitative, analytical, outcomes - afore emphasized - effect of Cerebrolysin, represents an - including mathematically based on - strong, objective reason to continue enlarging our studied groups.

Conclusions

Cerebrolysin administration proved to statistically significant improve the speed of achieving of, at least two key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE and WPB; actually, this goes with both, common sense (but mainly based on clinical evidence/expertise) and scientific information: modern pleiotropic drugs – Cerebrolysin is emblematic – obviously cannot cure the CNS lesions (not even provide complete restitution to lost functions) but they can instead, really hasten recovery.

Moreover, considering the objectified, imperious necessity to substantially enlarge the studied lots, of our study, we have now initiated a comprehensive, national, 5 year, retrospective, multi-centre (based on unitary data acquisition - see below - frame and mathematical apparatus) study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).
Cerebrolysin prescribed during hospitalization

| Moment of introduction | Period (days) | Quantity | Glasgow Outcome Score (GOS) at discharge | Cerebrolysin prescribed at discharge | Period (days) | Quantity |
|------------------------|--------------|---------|----------------------------------------|-----------------------------------|--------------|---------|
| 13                     |              |         |                                        |                                   |              |         |
| 14                     |              |         |                                        |                                   |              |         |
| 15                     |              |         |                                        |                                   |              |         |

References

1. **Muresanu D.** Neuroprotection and Neuroplasticity - two aspects of continuous process, genetically regulated and powered by neurotrophic factors. Communication at the 6th AMN Congress, April 2008, Cluj-Napoca, Romania.

2. **Fehlings MG, Baptiste DC.** Current status of clinical trials for acute spinal cord injury. *Injury* 2005; 36 (Suppl 2): B113–B122.

3. **Hall ED, Springer JE.** Neuroprotection and acute spinal cord injury: a reappraisal. *NeuroRx* 2004; 1: 80–100.

4. **Skvortsova VI, Stakhovska LV, Gubsky LV, Shamalov NA, Tikhonova IV, Smychkov AS.** Randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in treatment of acute ischemic stroke. *Zh Nevrol Psikhiatr Im S S Korsakova*; 2004; 11.

5. **Windisch M, Gschanes A, Hutter-Paier B.** Neurotrophic activities and therapeutic experience with a brain-derived peptide preparation, ageing and dementia. *J Neural Transm* 1998; Suppl 53.

6. **Onose G. et al.** Stem cells and Tissue engineering, basics for Regenerative Medicine. A synthetic overview. *Romanian Neurosurgery*, 14 (1): 4-18, 2007.

7. **Rowland J.W. și col.** Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. *Neurosurg Focus*, 25 (5): E2, 2008.

8. **Hall ED, Springer JE – Neuroprotection and acute spinal cord injury: a reappraisal. *NeuroRx* 2004; 1: 80-100.**

9. **Bracken MB, Shepard MJ, Collins WF et al.** A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. *N Engl J Med* 1990; 322: 1405-11.

10. **Bracken MB, Shepard MJ, Holford TR et al.** Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study, *JAMA* 1997; 277:1597-604.

11. **Hurlbert RJ.** Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. *J Neurosurg* 2000; 93: 1-7.

12. **Sayer FT, Kronvall E, Nilsson OG.** Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. *Spine* 2006; 6: 335-43.

13. **Blackman S.** A matter of life and cell death. *The Scientist*, 19(4): 22, 2005.

14. **Kartje GL, Schulz MK, Lopez-Yunez A, Schnell L, Schwab ME.** Corticostriatal plasticity is restricted by myelin-associated neurite growth inhibitors in the adult rat. *Ann Neurol* 1999; 45: 778–786.

15. **Buchli AD, Schwab ME.** Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system. *Ann Med* 2005; 37: 556–567.

16. **Schwab ME.** Nogo inhibition to enhance regeneration and functional recovery in SCI. *Summer School for the Biological Treatment of Chronic Spinal Cord Injury. Vienna, Austria, Oct. 2008*.

17. **McKerracher L. et al**. Targeting Rho to stimulate repair after spinal cord injury. *Top Spinal Cord Inj Rehabil*, 8: 69-75, 2003.

18. **Shao Z. et al.** TAJ/TROY an orphan FNT receptor family member, bind Nogo-66 receptor 1 and regulates axonal regeneration. *Neuron*, 45(3): 353, 2005.

19. **Abdelaziz O.** A potentially new pharmacological therapy for acute spinal cord injury (ASCI) effects of Cerebrolysin administration on experimental ASCI. Communication at the 6th AMN Congress, April 2008, Cluj-Napoca, Romania.

20. **Wronsik R, Kronawetter S, Hutter-Paier B, Craislheim K, Windisch M.** A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons. *J Neural Transm*, Suppl. 59: 263, 2000.

21. **Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R.** In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. *Neurotox Res.* 4: 59, 2002.